Immune modulation following α and β− radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model

Immune modulation following α and β− radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model

α- and β−-emitting radionuclides targeting human fibroblast activation protein-α (hFAP) are under investigation for cancer therapy. In prior work, analysis of the tumor microenvironment 24 h after therapy completion indicated therapy-induced immune activation. Here, we analyzed systemic immune respo...

Full description

Saved in:
Bibliographic Details
Main Authors: Hannelore Ceuppens, Kirsten De Ridder, Thomas Ertveldt, Katty Zeven, Wout De Mey, Ana Rita Pombo Antunes, Laurent Navarro, Nina Dumauthioz, Tony Lahoutte, Jens M. Debacker, Nick Devoogdt, Marleen Keyaerts, Matthias D’Huyvetter, Cleo Goyvaerts, Karine Breckpot
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
fibroblast activation protein-α
single domain antibody
targeted radionuclide therapy
immunostimulation
immunotherapy
cGAS-STING
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2540054
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items